


Superior Efficacy of Ozoralizumab, an anti-Human TNF Nanobody in a TNF Transgenic Mouse Model of Polyarthritis

Martin Hegen, Els Beirnaert, Guy Hermans, Peter Casteels, Marina Shen, Julie Lee, Lori Fitz, Yulia Vugmeyster, Christopher Wrocklage, Nilufer Seth, Kyri Dunussi-Joannopoulos, Cheryl Nickerson-Nutter, Mary Collins.

Disclosures:

Martin Hegen, Marina Shen, Julie Lee, Lori Fitz, Yulia Vugmeyster, Christopher Wrocklage, Nilufer Seth, Kyri Dunussi-Joannopoulos, Cheryl Nickerson-Nutter and Mary Collins are employees of Pfizer Inc.

Els Beirnaert, Guy Hermans and Peter Casteels are employees of Ablynx nv and hold stock in Ablynx nv.



Ozoralizumab (ATN-103): Humanized, Trivalent, Bi-specific Nanobody

- Novel humanized therapeutic protein derived from camelid heavy-chain antibody**
 - 38 kDa protein, one quarter the size of Adalimumab, Infliximab or Etanercept
- Two anti-TNF Nanobody building blocks**
 - Expected potency comparable with Etanercept
 - Humanized llama domain: 98% homology versus human
- One anti-HSA Nanobody building block**
 - Half-life extension
 - Humanized llama domain: 92% homology versus human


Model of Ozoralizumab complexed with TNF

4


Binding affinities of Ozoralizumab and TNF inhibitors to TNF

TNF inhibitor	Human TNF Kd (pM)	Rhesus TNF Kd (pM)
Ozoralizumab	20.2	16.1
Etanercept	11.6	24.2
Adalimumab	23.7	25.8
Infliximab	22.7	No binding

Ozoralizumab demonstrated identical equilibrium dissociation constants (*K_d*) based on binding to human and rhesus monkey albumin.




Flow Cytometry demonstrating Binding of Ozoralizumab to Cell Surface TNF





7

Ozoralizumab (ATN-103) has no Observed Complement-dependent Cytotoxicity (CDC) or Antibody-dependent Cell-mediated Cytotoxicity (ADCC) Activity



8


Effect of Ozoralizumab (ATN-103) on Neutrophil Infiltration



*significant at p<0.05 by the Student's t-test.

9

Ozoralizumab shows Superior Efficacy in the Human TNF Transgenic Tg197 Mouse Model of Arthritis



Human TNF transgenic Tg197 mouse




Biomedcode Hellas SA.

Ozoralizumab (ATN-103)
 Histopathological score:
 0: No detectable pathology
 1: Hyperplasia of the synovial membrane and presence of polymorphonuclear infiltrates
 2: Pannus and fibrous tissue formation and focal subchondral bone erosion
 3: Cartilage destruction and bone erosion
 4: Extensive cartilage destruction and bone erosion

10

PK Profiles of Ozoralizumab after a single IV or SC Dose to Cynomolgus Monkeys



- The mean half-life after a single IV or SC dose ranged from 7-10 days
- The bioavailability after a single SC dose was ~70%

Pharmacokinetic analysis in mice and in non-human primates confirmed the long *in vivo* half-life of Ozoralizumab

11

Conclusions:

- Ozoralizumab has high affinity for human TNF and showed equivalent potency on a molar basis as compared to Etanercept in a cell based assay
- Ozoralizumab has no observed complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) activity
- In comparison with Infliximab, Ozoralizumab demonstrated superior efficacy in a therapeutic treatment protocol in the human TNF transgenic mouse model of arthritis
- Pharmacokinetic analysis showed long *in vivo* half-life of Ozoralizumab in non-human primates

12

Please note:

- **Pharmacokinetic-Pharmacodynamic Modeling of Ozoralizumab (ATN-103), a Novel Humanized Nanobody TNF Inhibitor for Rheumatoid Arthritis**
Poster Presentation #125: Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy:
Monday, November 7, 9:00 AM - 6:00 PM

- **A Multiple Ascending Dose / Proof of Concept study of ATN-103 (ozoralizumab) in Rheumatoid Arthritis Subjects on a background of Methotrexate**
Oral Presentation #2630: Rheumatoid Arthritis Treatment - Small Molecules, Biologics, Therapy: Novel Compounds II
Wednesday, November 9, 11:00 AM - 12:30 PM
Presentation Time: **11:45 AM - 12:00 PM** Room W 375 A